ESMO/ECCO to host combined meetings

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Compared with standard therapy, dasatinib did not improve efficacy for patients with core-binding factor AML.

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD

June 9th 2025

Serplulimab Yields Sustained OS/PFS Benefits in Extensive-Stage SCLC

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

Biomarker analyses indicate the predictive potential of a 15-protein signature related to the efficacy of serplulimab plus chemotherapy in ES-SCLC.

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Biomarker analyses indicate the predictive potential of a 15-protein signature related to the efficacy of serplulimab plus chemotherapy in ES-SCLC.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD

June 5th 2025

Experts weigh in on the practical applications of PSMA PET imaging

Results of a post hoc analysis found spleen and symptom response rates to be comparable with ESAs or danazol in combination with ruxolitinib for patients with myelofibrosis who have anemia.

Iptacopan Yields Meaningful Hemoglobin Improvements in Pretreated PNH Group

Results of a post hoc analysis found spleen and symptom response rates to be comparable with ESAs or danazol in combination with ruxolitinib for patients with myelofibrosis who have anemia.

Data from APPULSE-PNH may support oral iptacopan as a potentially practice-changing option in patients with paroxysmal nocturnal hemoglobinuria.

Dasatinib Misses Survival End Points in Core-Binding Factor AML

Data from APPULSE-PNH may support oral iptacopan as a potentially practice-changing option in patients with paroxysmal nocturnal hemoglobinuria.

Related Content

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Compared with standard therapy, dasatinib did not improve efficacy for patients with core-binding factor AML.

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD

June 9th 2025

Serplulimab Yields Sustained OS/PFS Benefits in Extensive-Stage SCLC

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Biomarker analyses indicate the predictive potential of a 15-protein signature related to the efficacy of serplulimab plus chemotherapy in ES-SCLC.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD

June 5th 2025

Experts weigh in on the practical applications of PSMA PET imaging

Iptacopan Yields Meaningful Hemoglobin Improvements in Pretreated PNH Group

Results of a post hoc analysis found spleen and symptom response rates to be comparable with ESAs or danazol in combination with ruxolitinib for patients with myelofibrosis who have anemia.